Lim Juhyun, President of Hanmi Pharm, Appointed Director at US Partner Spectrum

[Asia Economy Reporter Lee Gwan-joo] Lim Joo-hyun, CEO of Hanmi Pharm, has been appointed as a director of Spectrum, a partner company in the United States.

Spectrum officially announced Lim's appointment as a director on the 11th, stating that Lim will play a role in contributing to various collaborations between the two companies for the commercialization of new drugs currently being developed by Spectrum.

Lim, who joined Hanmi Pharm in 2007, currently oversees the global strategies of various new drugs as the CEO of Hanmi Science, the holding company of Hanmi Pharm Group, and Hanmi Pharm. He also demonstrates leadership in the group's human resources development sector. Additionally, he holds a director position at Hanmi Ventures, a healthcare investment company.

William Ashton, Chairman of Spectrum's Board, said, "We are pleased that Lim has joined Spectrum's board at a time when we are dedicated to developing innovative new drugs for cancer patients," adding, "We expect Lim's leadership and experience at Hanmi Pharm to ideally contribute to the future growth of both companies."

Lim stated, "I am pleased to be able to support Spectrum's efforts for the global commercialization of Hanmi Pharm's core new drugs," emphasizing, "We will do our best to strengthen close cooperation between the two companies so that Hanmi's new drugs can be successfully launched in the U.S. market."

This content was produced with the assistance of AI translation services.